Home
EN / FR

Celyad Oncology

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

376_981be_rev-1

Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group

December 3, 2021
READ THE PRESS RELEASE

Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

November 12, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights

November 10, 2021
READ THE PRESS RELEASE

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition

November 4, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces November 2021 Conference Schedule

November 2, 2021
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

October 29, 2021
READ THE PRESS RELEASE

Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting

October 1, 2021
READ THE PRESS RELEASE

Celyad Oncology announces September 2021 Conference Schedule

September 1, 2021
READ THE PRESS RELEASE

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

August 4, 2021
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

July 30, 2021
READ THE PRESS RELEASE
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres-1

Celyad Oncology@CelyadSA·
21h

Today we announced the completion of a $32.5 million round of #financing for the company. Read more here: https://bit.ly/3xRz4rL $cyad

Celyad Oncology@CelyadSA·
2 Dec

We are included in the December issue of #lifescienceleader where our head of cell therapy manufacturing Thomas Lequertier discusses his thoughts on how #COVID19 will impact the biopharmaceutical supply chain. Read more here (free sign up!): https://buff.ly/32VmvAx

View All

Stay informed about the latest news!

Sign up FOR our newsletter

By clicking on “send”, you accept that your data will be sent to us and processed by our provider in order to send you our newsletter. You can find more information on how we process your data in our Privacy Policy.